Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs

Table 3 Predictors of low power Doppler activity (≤ 1) at 12 months

	Univariable analyses		Multivariable analyses*
	OR (95%CI)	P	OR (95% CI)	P
Overall population
CXCL13 third tertile	0.19 (0.07 to 0.54)	0.002	0.16 (0.04 to 0.58)	0.005
CRP third tertile	0.58 (0.21 to 1.56)	0.28	-	-
ESR third tertile	0.61 (0.22 to 1.7)	0.35	-	-
ACPA (positive)	0.40 (0.14 to 1.15)	0.09	0.41 (0.12 to 1.40)	0.15
baseline PD score (third tertile)	0.94 (0.31 to 2.83)	0.91	-	-
DAS < 2.4
CXCL13 third tertile	0.05 (0.01 to 0.42)	0.006	0.06 (0.01 to 0.55)	0.01
CRP third tertile	0.53 (0.12 to 2.37)	0.41	-	-
ESR third tertile	1.22 (0.22 to 6.72)	0.82	-	-
ACPA (positive)	0.46 (0.09 to 2.22)	0.33	-	-
baseline PD score (third tertile)	0.57 (0.11 to 2.86)	0.49	-	-

*Adjusted for age, gender, symptoms duration, glucocorticoid comedication, total amount of methotrexate administered and each of the variables with P < 0.2 in univariable analysis.
ACPA, anti-citrullinated protein antibodies; CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; PD, Power Doppler. CXCL13 third tertile: > 100 pg/ml. CRP third tertile: > 2.3 mg/dl. ESR third tertile: > 39 mm/1 h baseline PD score third tertile: > 7

ISSN: 1478-6362